Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Eli Lilly and Company and SiteOne Therapeutics, Inc., a private biotechnology company developing small molecule inhibitors of ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

LLY to acquire SiteOne for up to $1 billion. GSK's antibiotic study ends early for efficacy. MRNA loses H5 flu vaccine ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...